积极稳妥地进行治疗效果优化及新适应证探索研究,不断提高科学使用抗血管内皮生长因子药物治疗眼底病的临床应用水平

Optimization of treatment outcome and exploration of new indication in anti-vascular endothelial growth factor therapy

抗血管内皮生长因子（VEGF）药物治疗已经成为新生血管性老年性黄斑变性的临床一线治疗,在糖尿病黄斑水肿、视网膜静脉阻塞继发黄斑水肿以及早产儿视网膜病变、新生血管性青光眼等视网膜新生血管病变相关的疾病治疗中也得到广泛应用并取得良好的临床效果.然而,积极稳妥地进行治疗效果优化以及新的适应证探索研究,在国内外研究的基础上,结合本地区特点和患者具体情况,不断提高科学使用抗VEGF药物治疗眼底病的临床应用水平仍有大量工作要做;进一步深入研究新生血管性眼底疾病的本质特征以及影响其发生发展转归的相关因素,开发研究更新更好的治疗药物及方法尚任重道远.

Since anti vascular endothelial growth factor （VEGF） therapy has recently become the first-line treatment of wet age related macular degeneration in China,as well as retinopathy of prematurity,neovascular glaucoma and macular edema secondary to diabetic retinopathy or retinal vein occlusion in other countries,It is worth thinking about that how to perform anti-VEGF treatment properly to benefit more patients.We reviewed the fields of clinical researches to explore the best role of anti-VEGF treatment in prevention and treatment of retinal disease in future.